AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves.
$50.02+2.61%
报价 2026-11-06
市值
$2.99B
EV
$2.76B
PE (TTM)
–
预期 PE (FY2026)
90.2x
52 周区间距高点 -3.3%
$23.55$51.73
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中≈ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.4x | 0.47 → 0.71（1.5x） | 70.9 |
| FY+32028-12 | 1.7x | 0.47 → 0.97（2.1x） | 51.4 |
毛利率 74% · TTM 收入 $267M · 基数 EPS 0.47（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AXGNAxoGen, Inc. | $2.99B | +2.6% | +29.4% | 74.8% | – | – | 188.0x | |
| TSHATaysha Gene Therapies, Inc. | $1.41B | +5.9% | -66.1% | 94% | – | – | – | |
| OPKOPKO Health, Inc. | $1.29B | -1.1% | -4.7% | 48.9% | – | 26.2x | – | |
| TNDMTandem Diabetes Care, Inc. | $1.18B | -6.0% | +7.1% | 56.9% | – | – | – | |
| IRMDIRadimed Corporation | $1.1B | +0.9% | +10.3% | 76.8% | 56.2x | 42.1x | 65.4x | |
| IARTIntegra LifeSciences Holdings Corporation | $1.04B | -5.0% | +0.8% | 51% | 80.0x | 12.0x | 10.6x | |
| AHCOAdaptHealth Corp. | $999.4M | -1.1% | -10.8% | 15.4% | – | 36.8x | 12.2x | |
| INMDInMode Ltd. | $767.1M | -0.5% | – | 77.8% | 10.7x | 5.3x | – | Cheap |
| SANASana Biotechnology, Inc. | $709.5M | +1.3% | – | 0% | – | – | – | |
| 同行中位数 | – | – | -1.9% | 54% | 56.2x | 26.2x | 12.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $75.8M | $69.7M | $61.5M | $59.9M | $60.1M | $56.7M | $48.6M | $49.4M |
| Gross Margin | 74.8% | 72.7% | 75.2% | 74.1% | 76.6% | 74.2% | 71.9% | 76.1% |
| Operating Margin | 1.3% | -3.1% | -4.6% | -16.3% | 3.2% | 3% | -3.4% | 4.1% |
| Net Income | $2.3M | $-1.5M | $-19.6M | $-13.2M | $708,000 | $579,000 | $-3.8M | $450,000 |
| Diluted EPS | 0.04 | -0.03 | -0.38 | -0.28 | 0.01 | 0.01 | -0.08 | 0.01 |
| Operating Cash Flow | $16.5M | $1.5M | $1.6M | $3M | $3.2M | $7.7M | $-13.2M | $8.7M |